| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0014-2999(89)90184-2 |
| P698 | PubMed publication ID | 2542039 |
| P2093 | author name string | Humphrey PP | |
| Feniuk W | |||
| Connor HE | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 91-94 | |
| P577 | publication date | 1989-02-01 | |
| P1433 | published in | European Journal of Pharmacology | Q1376712 |
| P1476 | title | 5-Hydroxytryptamine contracts human coronary arteries predominantly via 5-HT2 receptor activation | |
| P478 | volume | 161 |
| Q72102090 | 5-HT receptors mediating contractions of the isolated human coronary artery |
| Q37739587 | 5-HT(1F) Receptor agonists: a new treatment option for migraine attacks? |
| Q55065936 | 5-Hydroxytryptamine (5-HT) contracts the guinea-pig isolated iliac artery via 5-HT1-like and 5-HT2 receptors. |
| Q68048853 | 5-Hydroxytryptamine-induced contractions of the human isolated saphenous vein: involvement of 5-HT2 and 5-HT1D-like receptors, and a comparison with grafted veins |
| Q77905372 | 5-Hydroxytryptamine-induced phosphoinositide hydrolysis and Ca2+ mobilisation in canine cultured aorta smooth muscle cells |
| Q46865690 | A case of myocardial infarction with sumatriptan use. |
| Q42185809 | A comparison of the contractile effects of 5-hydroxytryptamine, sumatriptan and MK-462 on human coronary artery in vitro |
| Q42106752 | Actions of non-peptide ergot alkaloids at 5-HT1-like and 5-HT2 receptors mediating vascular smooth muscle contraction |
| Q42281088 | Adverse reactions attributed to sumatriptan. A postmarketing study in general practice |
| Q35884789 | Augmented contraction of the human isolated coronary artery by sumatriptan: a possible role for endogenous thromboxane |
| Q77164374 | BMS-181885, a 5-HT1B/1D receptor ligand, in experimental models predictive of antimigraine activity and coronary side-effect potential |
| Q42171127 | Both 5-hydroxytryptamine 5-HT2A and 5-HT1B receptors are involved in the vasoconstrictor response to 5-HT in the human isolated internal thoracic artery |
| Q34481198 | Cardiovascular safety of 5HT1B/1D agonists--is there a cause for concern? |
| Q77899449 | Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques |
| Q43969535 | Characterization of sumatriptan-induced contractions in human isolated blood vessels using selective 5-HT(1B) and 5-HT(1D) receptor antagonists and in situ hybridization |
| Q35043008 | Collar-induced elevation of mRNA and functional activity of 5-HT(1B) receptor in the rabbit carotid artery. |
| Q48452959 | Comparative effects of the antimigraine drugs sumatriptan and ergotamine on the distribution of cardiac output in anaesthetized pigs |
| Q36330430 | Comparison of contractile responses to 5-hydroxytryptamine and sumatriptan in human isolated coronary artery: synergy with the thromboxane A2-receptor agonist, U46619 |
| Q44014671 | Comparison of contractile responses to donitriptan and sumatriptan in the human middle meningeal and coronary arteries |
| Q51471078 | Comparison of response to serotonin of radial artery grafts and internal mammary grafts to native coronary arteries and the effect of diltiazem. |
| Q35802749 | Comparison of the vasoconstrictor effects of rizatriptan and sumatriptan in human isolated cranial arteries: immunohistological demonstration of the involvement of 5-HT1B-receptors |
| Q36055018 | Comparison of the vasoconstrictor effects of the selective 5-HT1D-receptor agonist L-775,606 with the mixed 5-HT1B/1D-receptor agonist sumatriptan and 5-HT in human isolated coronary artery |
| Q35376658 | Complex stenosis morphology and vasomotor responses to inhibition of nitric oxide synthesis |
| Q35775292 | Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine |
| Q41816208 | Contractions to 5-hydroxytryptamine in human coronary artery and human saphenous vein |
| Q30932195 | Coronary vasoconstrictor potential of triptans: a review of in vitro pharmacologic data |
| Q42996284 | Coronary vasospasm and sumatriptan |
| Q44935647 | Effect of high-dose intravenous eletriptan on coronary artery diameter |
| Q42253035 | Effect of the thromboxane A2-mimetic U46619 on 5-HT1-like and 5-HT2 receptor-mediated contraction of the rabbit isolated femoral artery |
| Q54191072 | Effects of S20749, a close analogue of sumatriptan, on porcine carotid haemodynamics and human isolated coronary artery. |
| Q35872811 | Effects of U46619 on contractions to 5-HT, sumatriptan and methysergide in canine coronary artery and saphenous vein in vitro |
| Q46694107 | Effects of sumatriptan and eletriptan on diseased epicardial coronary arteries |
| Q42235624 | Evidence for 5-HT1-like receptor-mediated vasoconstriction in human pulmonary artery |
| Q35029098 | Functional characterization and m-RNA expression of 5-HT receptors mediating contraction in human umbilical artery |
| Q46892256 | Inhibition of 5-hydroxytryptamine receptor prevents occlusive thrombus formation on neointima of the rabbit femoral artery |
| Q42582014 | Mechanism of 5-hydroxytryptamine-induced coronary vasodilation assessed by direct detection of nitric oxide production in guinea-pig isolated heart |
| Q41958499 | Mechanism of actions of sumatriptan on coronary flow before and after endothelial dysfunction in guinea-pig isolated heart |
| Q39471681 | Migraine and cluster headache--their management with sumatriptan: a critical review of the current clinical experience |
| Q35783724 | Migraine headache misconceptions: barriers to effective care |
| Q42549327 | Naratriptan: biological profile in animal models relevant to migraine |
| Q33774494 | Pathophysiology of migraine--new insights. |
| Q73120081 | Pharmacological analysis of contractile effects of eletriptan and sumatriptan on human isolated blood vessels |
| Q33709238 | Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy |
| Q34793746 | Pharmacological reactivity of human epicardial coronary arteries: phasic and tonic responses to vasoconstrictor agents differentiated by nifedipine |
| Q44004694 | Pharmacology of the selective 5-HT(1B/1D) agonist frovatriptan |
| Q88760645 | Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers |
| Q38065274 | QT prolongation, Torsade de Pointes, myocardial ischemia from coronary vasospasm, and headache medications. Part 1: review of serotonergic cardiac adverse events with a triptan case |
| Q42538062 | Safety trial with the 5HT1B/1D agonist avitriptan (BMS-180048) in patients with migraine who have experienced pressure, tightness, and/or pain in the chest, neck, and/or throat following sumatriptan |
| Q74539260 | Serotonin and vasoconstrictor synergism |
| Q46627647 | Serotonin induces vasoconstriction of smooth muscle cell-rich neointima through 5-hydroxytryptamine2A receptor in rabbit femoral arteries |
| Q40478013 | Serotonin receptors: Subtypes, functional responses and therapeutic relevance |
| Q35684215 | Subcutaneous delivery of sumatriptan in the treatment of migraine and primary headache |
| Q43778294 | Sumatriptan and naratriptan tolerability and safety: an update of post-marketing experience |
| Q67508286 | Sumatriptan contracts large coronary arteries of beagle dogs through 5-HT1-like receptors |
| Q57025129 | Sumatriptan is a Potent Vasoconstrictor of Human Dural Arteries Via a 5-HT1-Like Receptor |
| Q37803238 | Sumatriptan therapy for headache and acute myocardial infarction |
| Q38180026 | Sumatriptan-associated ischemic colitis: case report and review of the literature and FAERS. |
| Q39485720 | Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache |
| Q35329290 | Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache |
| Q34403370 | The effect of i.v. sumatriptan, a selective 5-HT1-receptor agonist on central haemodynamics and the coronary circulation |
| Q42081184 | The effect of rizatriptan, ergotamine, and their combination on human peripheral arteries: a double-blind, placebo-controlled, crossover study in normal subjects |
| Q34373285 | The in vivo pharmacological profile of a 5-HT1 receptor agonist, CP-122,288, a selective inhibitor of neurogenic inflammation |
| Q51396268 | The in vivo pharmacological profile of eletriptan (UK-116,044): a potent and novel 5-HT(1B/1D) receptor agonist. |
| Q52243745 | The intracardiac neurones of the fetal human heart in culture. |
| Q35048015 | Tolerability of the triptans: clinical implications |
| Q34127399 | Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy |
| Q41010987 | Vascular reactivity of arterial coronary artery bypass grafts--implications for their performance |
| Q79907241 | [Clinical use of triptans in the management of migraine] |
Search more.